Calu-3 Xenograft Model Service for NSCLC

The Calu-3 xenograft model is a validated preclinical platform for evaluating therapeutic efficacy against HER2-amplified, well-differentiated non-small cell lung cancer (NSCLC), particularly in the adenocarcinoma context. Alfa Cytology delivers robust, reproducible Calu-3 xenograft studies powered by rigorous cell line authentication, standardized tumor inoculation protocols, and comprehensive endpoint analyses to accelerate your compound's progression from lead optimization to IND-enabling data packages.

Overview of Calu-3 Xenograft Model for NSCLC

The Calu-3 cell line was established in 1975 by Jorgen Fogh from the pleural effusion of a 25-year-old Caucasian male with lung adenocarcinoma who had received prior therapy with cytoxan, bleomycin, and adriamycin. Genetically, Calu-3 is characterized by ERBB2 (HER2) gene amplification, which drives hyperactivation of the PI3K/AKT/mTOR signaling axis, and is notably sensitive to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors such as erlotinib. Cytogenetically, the line exhibits a hypotriploid karyotype with approximately 20 marker chromosomes, absence of normal chromosomes 1, 13, 15, and 17, and a disomic X chromosome. Calu-3 cells display well-differentiated epithelial morphology with the capacity to form polarized monolayers, making them a unique model for studying barrier integrity, mucosal interactions, and drug transporter expression in the context of lung adenocarcinoma.

When implanted into immunodeficient murine hosts, Calu-3 cells form well-differentiated grade I adenocarcinomas that recapitulate key aspects of human lung adenocarcinoma biology, including tumor growth kinetics, angiogenic potential, and distinct stromal vessel architecture. A landmark study demonstrated that Calu-3 xenografts exhibit a stromal vessel phenotype (in contrast to the more common tumor vessel phenotype), making them uniquely sensitive to VEGFR tyrosine kinase inhibitors such as cediranib, which induced significant vascular disruption, increased hypoxia, and substantial tumor regression within 24 hours. The Calu-3 xenograft model has been extensively validated for evaluating targeted therapies, anti-angiogenic strategies, antibody-drug conjugates, and combination regimens, offering a reliable bridge between in vitro mechanistic findings and in vivo pharmacological outcomes in a physiologically relevant tumor microenvironment.

Fig 1. Silencing of SKIL inhibited malignant phenotype of NSCLC. (Ma, Fang, et al., 2020)

Cell Line Information: Calu-3

Calu-3 is among the most widely utilized human lung adenocarcinoma cell lines in preclinical oncology, serving as both an in vitro model for respiratory epithelial barrier function and a foundational in vivo platform for NSCLC drug development. The table below summarizes the essential characteristics of the Calu-3 cell line.

Our Services

Alfa Cytology provides comprehensive, GLP-compliant Calu-3 xenograft model services designed to support your preclinical oncology pipeline from lead optimization through IND-enabling studies. Our integrated platform combines rigorous cell line authentication (STR profiling), standardized tumor inoculation protocols, and advanced endpoint analyses—including tumor volume monitoring, body weight assessment, histopathological evaluation, and biomarker profiling—to deliver high-quality, reproducible data that meets regulatory expectations. Whether your program requires subcutaneous flank models for rapid compound screening, orthotopic implantation for tissue-specific microenvironment studies, or bioluminescent/luciferase-labeled Calu-3 derivatives for real-time tumor tracking, our scientific team tailors each study to your compound's unique mechanism of action and development milestones.

Workflow of Calu-3 Xenograft Model Construction

Establishing a robust Calu-3 xenograft model requires meticulous attention to cell line integrity, host selection, and standardized procedural execution. Alfa Cytology follows a rigorous, stepwise workflow to ensure consistent tumor engraftment, predictable growth kinetics, and reliable therapeutic readouts across all studies.

1. Cell Line Preparation and Quality Control: Calu-3 cells are expanded under standardized culture conditions (DMEM/F-12, 10% FBS, 37°C, 5% CO₂) and subjected to comprehensive quality control, including mycoplasma testing, short tandem repeat (STR) authentication against ATCC reference profiles, and viability assessment (>98% viability required) prior to inoculation.
2. Host Selection and Acclimatization: Immunodeficient mouse strains—most commonly athymic nude (nu/nu) or NOD/SCID gamma (NSG) mice aged 6–10 weeks—are selected based on study objectives. Animals are acclimatized for a minimum of 5–7 days under controlled environmental conditions (22±2°C, 12-hour light/dark cycle) with ad libitum access to sterilized food and water.
3. Tumor Cell Inoculation: Calu-3 cells are harvested at logarithmic growth phase, washed, and resuspended in serum-free medium mixed with Matrigel® (typically 1:1 ratio) to enhance engraftment efficiency. A standardized inoculum (e.g., 1×10⁶ to 5×10⁶ cells in 100–200 µL) is injected subcutaneously into the flank or orthotopically into the lung parenchyma, depending on the experimental design.
4. Tumor Monitoring and Randomization: Tumor development is monitored by palpation and caliper measurement up to three times weekly. Calu-3 tumors typically become palpable by days 10–14 and reach treatment-appropriate volumes (100–200 mm³) within 2–3 weeks. Once tumors reach the predetermined volume, mice are randomized into treatment groups (n≥5 per group) stratified by tumor size to minimize inter-group variability.
5. Treatment Administration and In-Life Observations: Test articles are administered according to the study protocol (route, frequency, and dose established per client requirements). Body weight, clinical signs, and tumor dimensions are recorded at defined intervals throughout the in-life phase to assess tolerability and preliminary efficacy signals. Studies typically run 4–6 weeks to accommodate the model's growth kinetics.
6. Endpoint Analysis and Data Collection: At study termination, tumors are excised, weighed, documented by digital imaging, and processed for downstream analyses. Endpoints include tumor growth inhibition (TGI), tumor regression rate, histopathology (H&E, IHC for tight junction proteins, EGFR, Ki-67), biomarker expression (Western blot, qPCR, flow cytometry), and pharmacokinetic/pharmacodynamic (PK/PD) correlation as applicable.

Fig 2. Calu-3 xenograft model construction workflow.

Case Study-Calu-3 Xenograft Model Development

In a representative preclinical study, Calu-3 cells were subcutaneously implanted into immunodeficient mice to evaluate the antitumor efficacy of a novel therapeutic candidate targeting HER2-driven NSCLC. Following tumor establishment and randomization, animals received the test compound or vehicle control according to a defined dosing schedule. Longitudinal tumor monitoring demonstrated dose-dependent tumor growth inhibition, with the high-dose cohort achieving statistically significant reduction in tumor volume compared to the control group. At study endpoint, excised tumors were analyzed by histopathology and immunohistochemistry to assess treatment-induced changes in proliferation markers (Ki-67), apoptotic indices (cleaved caspase-3), and HER2 pathway activation status. These data supported the compound's mechanism of action and provided critical preclinical evidence for downstream development decisions.

Why Choose Alfa Cytology?

Alfa Cytology is committed to delivering scientifically rigorous, operationally efficient Calu-3 xenograft services that align with your preclinical development timelines and regulatory requirements. Our differentiated capabilities include:

• Extensive experience with Calu-3 and other NSCLC cell line-derived xenograft (CDX) models, ensuring high engraftment rates and reproducible tumor growth kinetics in well-differentiated adenocarcinoma contexts.
• Flexible study design options encompassing subcutaneous, orthotopic, and metastatic model configurations, with optional bioluminescence imaging for real-time tumor tracking and longitudinal efficacy assessment.
• Comprehensive in-life and endpoint analytical packages, including tumor volume monitoring, body weight assessment, clinical pathology, histopathology, and biomarker analysis tailored to HER2/EGFR-driven oncology programs.
• Strict adherence to cell line authentication (STR profiling), mycoplasma screening, and GLP-compliant documentation standards to ensure data integrity and regulatory acceptance for IND submissions.
• Dedicated project management with transparent communication, milestone-driven reporting, and rapid turnaround times to keep your development program on schedule from proof-of-concept through IND-enabling studies.
• Competitive pricing and scalable capacity to accommodate projects ranging from single-agent proof-of-concept studies to large-scale combination therapy screens and ADC efficacy evaluations.

Contact Us

Ready to advance your HER2-driven NSCLC therapeutic program with a validated Calu-3 xenograft model? Contact us today to discuss your study requirements, receive a customized proposal, and partner with Alfa Cytology for reliable, high-quality preclinical data. Our scientific team is standing by to reach out and guide your compound from early-stage evaluation through IND-enabling studies.

For research use only. Not intended for any clinical use.